187 related articles for article (PubMed ID: 26176707)
21. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.
Gowrishankar K; Gunatilake D; Gallagher SJ; Tiffen J; Rizos H; Hersey P
PLoS One; 2015; 10(4):e0123410. PubMed ID: 25844720
[TBL] [Abstract][Full Text] [Related]
22. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
[TBL] [Abstract][Full Text] [Related]
24. RAC1 and melanoma.
Halaban R
Clin Ther; 2015 Mar; 37(3):682-5. PubMed ID: 25465943
[TBL] [Abstract][Full Text] [Related]
25. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
[TBL] [Abstract][Full Text] [Related]
26. Characterisation and outcome of RAC1 mutated melanoma.
Lodde GC; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Sucker A; Placke JM; Zaremba A; Albrecht LJ; Kowall B; Galetzka W; Becker JC; Tasdogan A; Zimmer L; Livingstone E; Hadaschik E; Schadendorf D; Ugurel S; Griewank K
Eur J Cancer; 2023 Apr; 183():1-10. PubMed ID: 36773463
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
28. Impact of point mutation P29S in RAC1 on tumorigenesis.
Rajendran V; Gopalakrishnan C; Purohit R
Tumour Biol; 2016 Nov; 37(11):15293-15304. PubMed ID: 27699663
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of Eps8 in oral squamous cell carcinoma promotes cell migration and invasion through integrin-dependent Rac1 activation.
Yap LF; Jenei V; Robinson CM; Moutasim K; Benn TM; Threadgold SP; Lopes V; Wei W; Thomas GJ; Paterson IC
Oncogene; 2009 Jul; 28(27):2524-34. PubMed ID: 19448673
[TBL] [Abstract][Full Text] [Related]
30. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
Blank C; Kuball J; Voelkl S; Wiendl H; Becker B; Walter B; Majdic O; Gajewski TF; Theobald M; Andreesen R; Mackensen A
Int J Cancer; 2006 Jul; 119(2):317-27. PubMed ID: 16482562
[TBL] [Abstract][Full Text] [Related]
31. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146
[TBL] [Abstract][Full Text] [Related]
33. The role of Rac1 in maintaining malignant phenotype of mouse skin tumor cells.
Kwei KA; Finch JS; Ranger-Moore J; Bowden GT
Cancer Lett; 2006 Jan; 231(2):326-38. PubMed ID: 15893875
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant melanoma cells while negatively regulating their migration activity.
Ishikawa Y; Tsunoda K; Shibazaki M; Takahashi K; Akasaka T; Masuda T; Maesawa C
Int J Oncol; 2012 Jul; 41(1):53-60. PubMed ID: 22469839
[TBL] [Abstract][Full Text] [Related]
35. A feedforward relationship between active Rac1 and phosphorylated Bcl-2 is critical for sustaining Bcl-2 phosphorylation and promoting cancer progression.
Chong SJF; Lai JXH; Qu J; Hirpara J; Kang J; Swaminathan K; Loh T; Kumar A; Vali S; Abbasi T; Pervaiz S
Cancer Lett; 2019 Aug; 457():151-167. PubMed ID: 31103719
[TBL] [Abstract][Full Text] [Related]
36. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.
Wang X; Li J; Dong K; Lin F; Long M; Ouyang Y; Wei J; Chen X; Weng Y; He T; Zhang H
Cell Signal; 2015 Mar; 27(3):443-52. PubMed ID: 25499621
[TBL] [Abstract][Full Text] [Related]
37. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
38. RAC1 as a Therapeutic Target in Malignant Melanoma.
Cannon AC; Uribe-Alvarez C; Chernoff J
Trends Cancer; 2020 Jun; 6(6):478-488. PubMed ID: 32460002
[TBL] [Abstract][Full Text] [Related]
39. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
[TBL] [Abstract][Full Text] [Related]
40. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]